Does UnitedHealthcare Cover Chemotherapy? Costs and Denials

UnitedHealthcare does cover chemotherapy. The benefit runs across its commercial, employer-sponsored, individual marketplace, and Medicare Advantage plans, and it reaches infused drugs given in a clinic, oral chemotherapy pills filled through the pharmacy benefit, and supportive drugs like anti-nausea medications and colony-stimulating factors. What varies — and what tends to decide whether a specific treatment goes through smoothly — is the plan type, the drug regimen your oncologist proposes, and whether that regimen matches nationally recognized cancer guidelines.¹

What Chemotherapy Is Covered

UnitedHealthcare’s oncology medication policy covers injectable oncology drugs and therapeutic radiopharmaceuticals under the medical benefit. That includes drugs given intravenously, intravesically, and intrathecally in outpatient settings: a doctor’s office, a freestanding clinic, or a hospital outpatient department.¹ Oral chemotherapy is also covered, but it typically runs through the pharmacy benefit instead of the medical benefit. For most commercial and Individual Exchange members, oral regimens are managed through the Optum Cancer Guidance Program.²

For Medicare Advantage members, the structure follows Original Medicare. Part B covers physician-administered chemotherapy in outpatient settings. Part D covers self-administered prescription cancer drugs, including oral chemotherapy and anti-nausea pills.³

Patients under 19 receive broader access: all chemotherapy agents are covered for cancer-related indications in pediatric cases, reflecting the national protocols pediatric oncology follows.⁴

How UnitedHealthcare Decides a Drug Is Medically Necessary

Coverage decisions rest primarily on the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium. Treatments carrying an NCCN Category of Evidence and Consensus rating of 1, 2A, or 2B are considered proven and medically necessary. A Category 3 rating generally means UnitedHealthcare treats the use as unproven and will not cover it. When a drug or indication isn’t addressed in the NCCN Compendium, coverage falls back on FDA labeling.⁴

There’s a narrow opening even for treatments labeled unproven. Some UnitedHealthcare benefit plans allow coverage of experimental or investigational treatments for life-threatening illnesses when specific conditions are met. If a denial cites this reasoning, read the plan documents closely before accepting it.⁴

Prior Authorization

UnitedHealthcare requires prior authorization for outpatient injectable chemotherapy. The requirement sweeps in a wide range of billing codes (J9000 through J9999, Q-coded drugs, and miscellaneous HCPCS codes) along with related treatments like colony-stimulating factors, bone-modifying agents such as denosumab, and anti-nausea drugs used for cancer care. Oral chemotherapy also requires prior authorization for most commercial plans, routed through the Optum Cancer Guidance Program.²

Your oncologist’s office submits the request through the UnitedHealthcare Provider Portal. When the proposed regimen matches NCCN guidelines, approval often comes back at the time of submission. For regimens outside NCCN recommendations, rare cancers, or pediatric cases, UnitedHealthcare responds within three to five business days when the provider submits enough supporting documentation up front.⁵

Most authorizations last 365 days, though specific windows vary by treatment. Only one authorization is active per patient per regimen, and starting a new regimen automatically terminates the prior one. Adding a new injectable to a regimen requires a new authorization; dropping one does not.⁵

If treatment proceeds without prior authorization, the claim will be denied. Under UnitedHealthcare’s provider contracts, the clinic cannot bill you for that denied amount. The financial exposure for skipping the step sits with the provider, not the patient.⁵

Preferred Drugs, Biosimilars, and Step Therapy

UnitedHealthcare keeps a list of preferred oncology products, and patients starting a new therapy are generally required to begin with the preferred option. In practice, that often means a biosimilar instead of the originator brand. Mvasi is preferred over Avastin for bevacizumab. Kanjinti is preferred over Herceptin for trastuzumab. Ruxience is preferred over Rituxan for rituximab.⁴

You can receive a non-preferred product when your physician documents a history of intolerance or contraindication to the preferred drug and attests the same reaction wouldn’t be expected with the alternative.¹

Medicare Advantage members face a formal step therapy program for Part B drugs. These protocols require trying a preferred agent before a non-preferred one is covered, and they span several oncology drug classes: bevacizumab, trastuzumab, rituximab, pemetrexed, and PD-1/PD-L1 checkpoint inhibitors.⁶

If you’re already on a drug, there’s an important protection. A member with a paid claim for a drug within the past 365 days is not required to switch to a preferred product. This continuation-of-therapy rule prevents disruption mid-treatment.⁶

What Chemotherapy Will Cost

Out-of-pocket costs for chemotherapy depend heavily on plan type, and UnitedHealthcare directs members to the number on their insurance card for specifics.³

Medicare Advantage members getting chemotherapy under Part B pay the standard Medicare cost sharing: 20% of the Medicare-approved amount plus the Part B deductible when treated in a doctor’s office or freestanding clinic, or a copayment in a hospital outpatient setting.³

For oral chemotherapy and other Part D prescription cancer drugs, Medicare now caps annual out-of-pocket spending at $2,000, after which the member pays nothing for covered prescriptions for the rest of the year. Members can also use the Medicare Prescription Payment Plan to spread drug costs across the year instead of absorbing large payments at the pharmacy counter. Infused biologics covered under Part B are not subject to the Part D cap.⁷

In-Network Care and Surprise Billing

Most UnitedHealthcare plans cost more out of network, and some plans don’t cover out-of-network care at all.⁸ If a needed cancer treatment or oncology specialist isn’t available in-network, UnitedHealthcare may authorize an out-of-network provider at in-network cost sharing. The physician has to notify UnitedHealthcare, and the insurer has to confirm the service isn’t available in-network.⁹

The No Surprises Act adds a federal protection: when you’re treated at an in-network facility, ancillary services like pathology and radiology (both routine in cancer treatment) can’t be balance-billed even if the individual provider is out of network. You pay in-network rates for those services.¹⁰

Oral Chemotherapy Parity Laws

Because oral cancer drugs run through the pharmacy benefit, they can carry higher out-of-pocket costs than infused equivalents. To address this, 43 states and Washington, D.C. have passed oral anticancer medication parity laws requiring coverage of oral cancer drugs to be no less favorable than coverage for infused or injected versions. Oregon enacted the first in 2008, and most other states followed by 2019.¹¹

These state laws apply to fully insured private health plans. They do not cover Medicare, Medicaid, or self-funded employer plans, which fall under federal law. No federal oral chemotherapy parity law exists, though bills like the Cancer Drug Parity Act have been introduced in Congress.¹² Whether this protection reaches a given UnitedHealthcare member depends on state and plan type.

Clinical Trials

Under the Affordable Care Act, UnitedHealthcare must cover routine patient costs for qualified members in approved clinical trials for cancer or other life-threatening conditions. That means the standard services you’d receive regardless of trial enrollment — administration, monitoring, complication prevention — are covered even when the trial involves an experimental drug. The experimental agent itself is provided by the trial sponsor, not the insurer.¹³

Qualifying trials must be Phase I through IV and approved or funded by entities like the National Institutes of Health, the FDA, the Department of Defense, or the VA. UnitedHealthcare can’t deny routine coverage solely because a trial takes place out of state, though the plan may still require use of network providers if they participate in the trial.¹³

CAR-T Cell Therapy

CAR-T and tumor-infiltrating lymphocyte cell therapies fall outside UnitedHealthcare’s standard oncology medication policy. These treatments are managed through OptumHealth Transplant Solutions and may be covered as an autologous stem cell therapy under a member’s transplantation services benefit.⁴ Charges for a single CAR-T episode can exceed $2 million, and the managed program covers related services from one day before infusion through up to 90 days after.¹⁴

Optum’s clinical guidelines cover all seven FDA-approved CAR-T agents: Yescarta, Kymriah, Breyanzi, Carvykti, Tecartus, Abecma, and Aucatzyl. The treating facility must be certified by the Foundation for the Accreditation of Cellular Therapy, or actively pursuing that certification. Each request is reviewed individually against peer-reviewed literature and current FDA and NCCN recommendations.¹⁵

If Your Chemotherapy Is Denied

Denied chemotherapy claims can be appealed, and the process is worth pursuing. Research suggests people who appeal insurance denials succeed at least half the time.¹⁶

Start by checking whether the denial came from a clerical problem: a wrong billing code, missing paperwork, or incomplete information. Your provider’s billing department can often fix those by resubmitting. If the denial stands, you can file an internal appeal with UnitedHealthcare online, by mail, or by fax. Include the denial letter, medical records, and a physician’s statement explaining medical necessity. Standard internal reviews must be decided within 30 calendar days. Urgent cases involving a serious threat to health require a response within three days.¹⁷

If the internal appeal is denied, you can request an external review by an independent medical professional. The deadline is generally four months from the internal denial, and the external reviewer’s decision is final. In urgent situations, an expedited external review can be filed at the same time as the internal appeal. Your state’s Department of Insurance can also help you through the process.¹⁸

A Recent Settlement Over Cancer Coverage Denials

UnitedHealthcare has faced class action litigation over cancer treatment denials. The most prominent recent case, Weissman v. UnitedHealthcare Insurance Company, was filed in 2019 and alleged the insurer wrongfully denied proton beam radiation therapy by labeling it experimental. A federal judge granted final approval to a settlement on December 12, 2025.¹⁹

The agreement made up to $6.75 million available for patient reimbursement, with eligible class members able to receive up to $75,000 each for out-of-pocket costs tied to proton beam therapy for prostate, central nervous system, or cervical cancer. The settlement period covered denials between March 2016 and August 2023. UnitedHealthcare admitted no wrongdoing.²⁰ As part of the deal, UnitedHealthcare eliminated a list of 13 diagnoses its medical policy had previously labeled “unproven and not medically necessary” for proton beam therapy.²¹ The practical takeaway for members today: coverage policies can and do shift, and a denial that cites a treatment as unproven isn’t necessarily the last word.

1
UHC Provider. Oncology Medication Clinical Coverage Policy
2
UHC Provider. Oncology Injectable Chemo Prior Auth
3
UHC. Medicare Coverage for Cancer Screenings, Chemo and Radiation
4
UHC Provider. Oncology Medication Clinical Coverage Policy (Medical Drug)
5
UHC Provider. Prior Auth Injectable Chemo FAQ
6
UHC Provider. Medicare Part B Step Therapy Programs
7
Counterforce Health. UnitedHealthcare’s Specialty Drug Coverage and the $2,000 Cap
8
UHC. Choosing a Doctor
9
UHC. Commercial Plans Provider Information
10
U.S. Department of Labor. Avoid Surprise Healthcare Expenses
11
PMC. Oral Anticancer Medication Parity Laws
12
Journal of Hematology Oncology Pharmacy. Federal Oral Parity Legislation for Anticancer Drugs Awaits Action From Senate
13
UHC Provider. Clinical Trials Policy
14
Optum. Managed Cell Therapy Program
15
UHC Provider. Chimeric Antigen Receptor T-Cell (CAR T) Therapy Clinical Guidelines
16
Cancer Today Magazine. How Do You Appeal an Insurance Denial
17
UHC. Member Appeals and Grievances
18
Cancer Support Community. How to File a Health Insurance Appeal for a Denied Claim
19
Becker’s Payer. UnitedHealth Settles Cancer Coverage Suit
20
United PBT Settlement. Weissman v. UnitedHealthcare Settlement
21
Star Tribune. UnitedHealthcare Part of Settlement Over Denied Coverage for Costly Cancer Treatment